Clinical trials: Apixaban
Healthy Volunteers
Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets.
- Trial name
- NCT03509883
- Testing
- Drug: Apixaban sprinkle capsules, Experimental: Apixaban tablets followed by apixaban sprinkle capsules
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard…
- Trial name
- NCT00852397
- Testing
- Apixaban
- Where
- 18 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Pfizer
Venous Thrombosis
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis…
- Trial name
- NCT00633893
- Testing
- Apixaban
- Where
- 428 sites in United States, Argentina and 27 more
- Volunteers
- 2,711 people
- Sponsor
- Bristol-Myers Squibb
Post-Operative Atrial Fibrillation
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to…
- Trial name
- ATLAS (NCT02701062)
- Testing
- AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
- Where
- 22 sites in United States
- Volunteers
- 562 people
- Sponsor
- AtriCure, Inc.
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban.
- Trial name
- COBRRA Pilot (NCT02559856)
- Testing
- Apixaban, Rivaroxaban
- Where
- 4 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Ottawa Hospital Research Institute
Atrial Fibrillation
Medical Need of OAC Reversal
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
- Trial name
- NCT03254147
- Testing
- warfarin, dabigatran, Apixaban
- Where
- Japan
- Volunteers
- 53,969 people
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease
Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis
The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg Apixaban in subjects with normal renal function and subjects with end stage renal disease (ESRD) maintained with hemodialysis.
- Trial name
- NCT01340586
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Venous Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and…
- Trial name
- ADOPT (NCT00457002)
- Testing
- Apixaban, Enoxaparin
- Where
- 296 sites in United States, Argentina and 33 more
- Volunteers
- 6,758 people
- Sponsor
- Bristol-Myers Squibb
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare…
- Trial name
- ADVANCE-2 (NCT00452530)
- Testing
- Enoxaparin, Apixaban
- Where
- 122 sites in Austria, Belgium and 25 more
- Volunteers
- 3,221 people
- Sponsor
- Bristol-Myers Squibb
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban…
- Trial name
- NCT00423319
- Testing
- Enoxaparin, Apixaban
- Where
- 143 sites in United States, Argentina and 19 more
- Volunteers
- 5,407 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Vitamin K-antagonists (VKA) such as warfarin are the most widely used blood thinners for irregular heart beats like atrial fibrillation.
- Trial name
- NCT02090075
- Testing
- apixaban, warfarin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Aortic Valve Disease, Aortic Valve Stenosis
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
Currently, warfarin is the only approved anticoagulation for patients with mechanical valves. The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve can be maintained…
- Conditions
- Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure
- Trial name
- NCT04142658
- Testing
- Apixaban 5 MG, Apixaban 2.5 MG, Warfarin
- Where
- 62 sites in United States
- Volunteers
- 863 people
- Sponsor
- Artivion Inc.
Venous Thromboembolism, Menstruation
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
- Trial name
- (RAMBLE) (NCT02829957)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Venous Thromboembolism
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
- Trial name
- COVET (NCT03196349)
- Testing
- Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Bleeding
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
"This is a single-center, randomized, double-blind, and placebo-controlled trial designed to: 1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A (FXa)-inhibitor induced anticoagulation; and…
- Trial name
- NCT03310021
- Testing
- Andexanet alfa, Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Bleeding
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
- Trial name
- NCT02207725
- Testing
- Andexanet
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals